These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
Pubmed for Handhelds
PUBMED FOR HANDHELDS
Journal Abstract Search
2577 related items for PubMed ID: 24825642
1. Effect of evolocumab or ezetimibe added to moderate- or high-intensity statin therapy on LDL-C lowering in patients with hypercholesterolemia: the LAPLACE-2 randomized clinical trial. Robinson JG, Nedergaard BS, Rogers WJ, Fialkow J, Neutel JM, Ramstad D, Somaratne R, Legg JC, Nelson P, Scott R, Wasserman SM, Weiss R, LAPLACE-2 Investigators. JAMA; 2014 May 14; 311(18):1870-82. PubMed ID: 24825642 [Abstract] [Full Text] [Related]
2. Efficacy and Tolerability of Evolocumab vs Ezetimibe in Patients With Muscle-Related Statin Intolerance: The GAUSS-3 Randomized Clinical Trial. Nissen SE, Stroes E, Dent-Acosta RE, Rosenson RS, Lehman SJ, Sattar N, Preiss D, Bruckert E, Ceška R, Lepor N, Ballantyne CM, Gouni-Berthold I, Elliott M, Brennan DM, Wasserman SM, Somaratne R, Scott R, Stein EA, GAUSS-3 Investigators. JAMA; 2016 Apr 19; 315(15):1580-90. PubMed ID: 27039291 [Abstract] [Full Text] [Related]
13. Safety and efficacy of ezetimibe added on to rosuvastatin 5 or 10 mg versus up-titration of rosuvastatin in patients with hypercholesterolemia (the ACTE Study). Bays HE, Davidson MH, Massaad R, Flaim D, Lowe RS, Tershakovec AM, Jones-Burton C. Am J Cardiol; 2011 Aug 15; 108(4):523-30. PubMed ID: 21596364 [Abstract] [Full Text] [Related]
14. Achieving goal lipid levels with ezetimibe plus statin add-on or switch therapy compared with doubling the statin dose. A pooled analysis. Ambegaonkar BM, Tipping D, Polis AB, Tomassini JE, Tershakovec AM. Atherosclerosis; 2014 Dec 15; 237(2):829-37. PubMed ID: 25463129 [Abstract] [Full Text] [Related]
18. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia: the Reduction of LDL-C with PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Raal F, Scott R, Somaratne R, Bridges I, Li G, Wasserman SM, Stein EA. Circulation; 2012 Nov 13; 126(20):2408-17. PubMed ID: 23129602 [Abstract] [Full Text] [Related]